ACTRN12619001051134已完成1 期
A pilot study of an old drug with a new use – prochlorperazine to improve anti-EGFR therapy in squamous cell carcinoma of the mucosa
niversity Of Queensland0 个研究点目标入组 5 人开始时间: 2019年7月26日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
In summary it was found that EGFR can be re-localised to the surface of tumours temporarily and reversibly in patients and the study moved forward to a Phase IB dose escalation study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Histologically confirmed squamous cell carcinoma of head and neck mucosa
- •Tumour of any stage amenable to biopsy
排除标准
- •Eastern Cooperative Oncology Group (ECOG) performance status equal to or greater than 2; On drugs that cause long QTc ; History of prolonged QT interval or prolonged QT interval on baseline ECG; Systolic blood pressure less than 90mmHg and/or diastolic blood pressure < 50 mmHg in two consecutive blood pressure readings within the 1 hour prior to study drug administration; Previous reaction to antipsychotic medications requiring medical intervention; Pregnant or breast feeding
- •Excluded if Parkinson’s disease.
研究者
相似试验
已完成
2 期
Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLCNon-small Cell Lung CancerNCT01528488Sun Yat-sen University118
已完成
2 期
Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side EffectsColorectal CancerPancreatic CancerNon-small Cell Lung CancerNCT02284139Dong-A University Hospital90
已完成
1 期
A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor PatientsAdvanced CancerRefractory CancerNCT00551850AVEO Pharmaceuticals, Inc.37
进行中（未招募）
不适用
A Study to Evaluate JAK Inhibitor Cream in EGFR-inhibitor-induced Skin RashAcneiform EruptionsNCT05120362Shanghai East Hospital12
Unknown
不适用
Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)Non Small Cell Lung CancerEGFR-TKI Resistant MutationEGFR-TKI Sensitizing MutationNCT02661009GenoSaber1,000